

Basic science (February 2006)

- Abdelrahim M, Ariazi E, Kim K, Khan S, Barhoumi R, Burghardt R, Liu SX, Hill D, Finnell R, Wlodarczyk B, Jordan VC, Safe S. 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. *Cancer Res* 2006; **66**: 2459–2467.
- Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, Concannon P. The CHEK2*1100de/C allelic variant and risk of breast cancer: screening results from the breast cancer family registry. *Cancer Epidemiol Biomark Prevent* 2006; **15**: 348–352.
- Besada V, Diaz M, Becker M, Ramos Y, Castellanos-Serra L, Fichtner I. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. *Proteomics* 2006; **6**: 1038–1048.
- Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. *Modern Pathol* 2006; **19**: 238–245.
- Brew CT, Aronchik I, Hsu JC, Sheen JH, Dickson RB, Bjeldanes LF, Firestone GL. Indole-3-carbinol activates the ATM signaling pathway independent of DNA damage to stabilize p53 and induce G1 arrest of human mammary epithelial cells. *Int J Cancer* 2006; **118**: 857–868.
- Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. *J Pathol* 2006; **208**: 350–355.
- Chen SN, Iversen ES, Friebe T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutsch M, Kerber R, Amos CI, Strong LC, Berry DA, Euthus DM, Parmigiani G. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. *J Clin Oncol* 2006; **24**: 863–871.
- Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgars D, Spurdle ABGAKI. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. *Cancer Res* 2006; **66**: 2019–2027.
- Cheng ASL, Jin VX, Fan MY, Smith LT, Liyanarachchi S, Yan PS, Leu YW, Chan MWY, Plass C, Nephew KP, Davuluri RV, Huang THM. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. *Mol Cell* 2006; **21**: 393–404.
- Chooniedass-Kothari S, Hamedani MK, Troup S, Hube F, Leygue E. The steroid receptor RNA activator protein is expressed in breast tumor tissues. *Int J Cancer* 2006; **118**: 1054–1059.
- Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. *Clin Cancer Res* 2006; **12**: 1168–1174.
- Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. *Mol Cell* 2006; **21**: 555–564.
- Deckers M, van Dinther M, Buijs J, Que N, Lowik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer Res* 2006; **66**: 2202–2209.
- Diallo R, Rody A, Jackisch C, Ting E, Schaefer KL, Kissler S, Karn T, Gedert H, Engels K, Kaufmann M, Gabbert HE, Shroyer KR, Poremba C. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. *Hum Pathol* 2006; **37**: 205–211.
- Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. *Cancer Res* 2006; **66**: 2468–2475.
- Fowler AM, Solodin NM, Valley CC, Alarid ET. Altered target gene regulation controlled by estrogen receptor-alpha concentration. *Mol Endocrinol* 2006; **20**: 291–301.
- Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. *Brit J Cancer* 2006; **94**: 524–531.
- Gazzerro P, Abbondanza C, D'Arcangelo A, Rossi M, Medici N, Moncharmont B, Puca GA. Modulation of RIZ gene expression is associated to estradiol control of MCF-7 breast cancer cell proliferation. *Exp Cell Res* 2006; **312**: 340–349.

19. Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, Bardou VJ, Houvenaegel G, Jacquemier J, Granjeaud S, Meng XY, Fung ET, Birnbaum D, Maraninchi D, Viens P, Borg JP. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. *Oncogene* 2006; **25**: 981–989.
20. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. *Mol Cancer Ther* 2006; **5**: 356–361.
21. Harvell DME, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. *Endocrinology* 2006; **147**: 700–713.
22. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PFM, Spillane JB, Hopper JL, Martin TJ. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. *Cancer Res* 2006; **66**: 2250–2256.
23. Hiraga T, Myoui A, Choi ME, Yoshikawa I, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. *Cancer Res* 2006; **66**: 2067–2073.
24. Hockings JK, Thorne PA, Kemp MQ, Sherif SM, Selmin O, Romagnolo DF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. *Cancer Res* 2006; **66**: 2224–2232.
25. Hsu MC, Chang HC, Hung WC. HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. *J Biol Chem* 2006; **281**: 4718–4725.
26. Huggins GS, Wong JYY, Hankinson SE, De Vivo I. GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism. *Cancer Res* 2006; **66**: 1384–1390.
27. Jiang SM, Meyer R, Kang KY, Osborne CK, Wong JM, Oesterreich S. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. *Mol Endocrinol* 2006; **20**: 311–320.
28. Klos KS, Wyszomierski SL, Sun MH, Tan N, Zhou XY, Li P, Yang WT, Yin GS, Hittelman WN, Yui DH. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. *Cancer Res* 2006; **66**: 2028–2037.
29. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang GR, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. *Cancer Res* 2006; **66**: 1630–1639.
30. Konopleva M, Zhang WG, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu DH, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. *Mol Cancer Ther* 2006; **5**: 317–328.
31. Kwak EL, Kim S, Zhang JM, Cardiff RD, Schmidt EV, Haber DA. Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. *Cancer Res* 2006; **66**: 1923–1928.
32. Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippel P. The cyclooxygenase-2 (PTGS2) 8473T > C polymorphism is associated with breast cancer risk. *Clin Cancer Res* 2006; **12**: 1392–1394.
33. Li CX, Kato M, Shiue L, Shively JE, Ares M, Lin RJ. Cell type and culture condition-dependent alternative splicing in human breast cancer cells revealed by splicing-sensitive microarrays. *Cancer Res* 2006; **66**: 1990–1999.
34. Li J, Zou C, Bai Y, Wazer DE, Band V, Gao Q. DSS1 is required for the stability of BRCA2. *Oncogene* 2006; **25**: 1186–1194.
35. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. *Clin Cancer Res* 2006; **12**: 1175–1183.
36. Mallepell S, Krust A, Chambon P, Briskin C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. *Proc Natl Acad Sci USA* 2006; **103**: 2196–2201.
37. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, Eccles D, Douglas F, Paterson J, Hodgson S, Izatt L, Cole T, Burgess L, Eeles R, Easton DFGAEC. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Res* 2006; **66**: 1866–1872.
38. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, Foufelle F, Billaud M, Lenoir GM, Dalla Venezia N. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. *J Biol Chem* 2006; **281**: 3172–3181.
39. Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. *Hum Mol Genet* 2006; **15**: 599–606.
40. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M, Uzan S, Lotz JP, Touboul E, Lacave R. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. *Brit J Cancer* 2006; **94**: 473–480.
41. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. *Cancer Res* 2006; **66**: 1824–1832.
42. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res* 2006; **12**: 1157–1167.
43. Park CC, Zhang H, Paravicini M, Gray JW, Baehner F, Park CJ, Bissell MJ. Beta(1) integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. *Cancer Res* 2006; **66**: 1526–1535.

44. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SAA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM. Low-fat dietary pattern and risk of invasive breast cancer – the women’s health initiative randomized controlled dietary modification trial. *Jama-J Am Med Assoc* 2006; **295**: 629–642.
45. Rayala SK, Mascarenhas J, Vadlamudi RK, Kumar R. Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. *Mol Cancer Ther* 2006; **5**: 230–237.
46. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, Aldaz M, Khan S, Kumar R. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. *Cancer Res* 2006; **66**: 1694–1701.
47. Richardson AL, Wang ZGC, De Nicolo A, Lu X, Brown M, Miron A, Liao XD, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell* 2006; **9**: 121–132.
48. Ruan WF, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: Mediated through somatostatin subtype receptor 3? *Mol Endocrinol* 2006; **20**: 426–436.
49. Rudland SDS, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R, Rudland P. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. *Clin Cancer Res* 2006; **12**: 1192–1200.
50. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. *Cancer Res* 2006; **66**: 2391–2402.
51. Saffholm A, Leandersson K, Dejmek J, Nielsen CK, Villoutreix BO, Andersson T. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. *J Biol Chem* 2006; **281**: 2740–2749.
52. Sarvilinna N, Eronen H, Miettinen S, Viononen A, Ylikomi T. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. *Int J Cancer* 2006; **118**: 832–840.
53. Scott GK, Mattie ND, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. *Cancer Res* 2006; **66**: 1277–1281.
54. Shen YP, Li DK, Wu JQ, Zhang ZB, Gao ES. Joint effects of the CYP1A1 MspI, ER alpha PvuII, and ER alpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. *Cancer Epidemiol Biomark Prevent* 2006; **15**: 342–347.
55. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. Significance of Skp2 expression in primary breast cancer. *Clin Cancer Res* 2006; **12**: 1215–1220.
56. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HYI, Eaves CJ. Purification and unique properties of mammary epithelial stem cells. *Nature* 2006; **439**: 993–997.
57. Stylianou S, Clarke RB, Brennan K. Aberrant activation of Notch signaling in human breast cancer. *Cancer Res* 2006; **66**: 1517–1525.
58. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. *Cancer Res* 2006; **66**: 2476–2482.
59. Xia WL, Bisi J, Strum J, Liu LH, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao QY, Westlund RE, Zhao SM, Bacus S, Spector NL. Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. *Cancer Res* 2006; **66**: 1640–1647.
60. Xue CS, Liang FB, Mahmood R, Vuolo M, Wyckoff J, Qian H, Tsai KL, Kim M, Locker J, Zhang ZY, Segall JE. ErbB3-dependent motility and intravasation in breast cancer metastasis. *Cancer Res* 2006; **66**: 1418–1426.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia